![]() ![]() ![]() In addition to these diseases, briquilimab is being developed as a transformational non-genotoxic conditioning agent for gene therapy. Previous research has shown briquilimab to demonstrate efficacy and safety in over 130 patients with severe combined immunodeficiency, acute myeloid leukemia, MDS, sickle cell disease, and Fanconi anemia. We are excited to test briquilimab in the LR-MDS setting,” said Jeffery Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, in a press release.īriquilimab is a novel antibody therapy targeting c-Kit to address diseases such as lower to intermediate risk myelodysplastic syndromes (LR-MDS), chronic spontaneous urticaria, and novel stem cell transplant conditioning regimes. By directly targeting and depleting the diseased stem cells, briquilimab has the potential to restore bone marrow to a healthier and more functional state, with the ultimate goal of improved long-term outcomes and quality of life. “LR-MDS patients often face limited treatment options that primarily focus on increasing blood cell production and survival rather than restoring normal blood homeostasis. The first patient has been dosed in a phase 1 trial (NCT05903274) of briquilimab (JSP191) as second-line therapy in subjects with lower-risk myelodysplastic syndrome, according to Jasper Therapeutics. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |